Filing Flows › Ocular Therapeutix (OCUL) › Q2 2026 › vs Q2 2025
Ocular Therapeutix (OCUL) Q2 2026 vs Q2 2025 (year over year)
Ocular Therapeutix's revenue rose $16K (+0.1%) from $13.5M in Q2 2025 to $13.5M in Q2 2026.
Ocular Therapeutix, Q2 2026: revenue $13.5M (+0.1% year over year), operating margin -609.3%, net loss $78.8M, operating cash flow −$67.3M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $13.5M | $13.5M | $16K | +0.1% |
| Other income, net | $3.3M | −$173K | $3.5M | — |
| Net loss | $78.8M | $67.8M | $10.9M | +16% |
| Costs & expenses | $95.6M | $81.3M | $14.3M | +18% |
| Operating costs | $95.6M | $81.1M | $14.5M | +18% |
| Cost of revenue | $2.0M | $1.9M | $67K | +3% |
| Research & development | $54.1M | $51.1M | $3.1M | +6% |
| Sales & marketing | $17.3M | $13.7M | $3.5M | +26% |
| General & admin | $22.2M | $14.3M | $7.8M | +54% |
| Operating cash sources | $83.8M | $65.9M | $17.8M | +27% |
| Depreciation & amortization | $1.9M | $1.0M | $825K | +80% |
| Share-based compensation | $14.6M | $9.7M | $5.0M | +51% |
| Cash used in operations | $67.3M | $55.2M | $12.0M | +22% |
| Net loss absorbed | $78.8M | $67.8M | $10.9M | +16% |
| Working capital & other | $5.0M | −$1.9M | $6.9M | — |
Questions
How much did Ocular Therapeutix's revenue grow year over year in Q2 2026?
Ocular Therapeutix's revenue rose $16K (+0.1%) from $13.5M in Q2 2025 to $13.5M in Q2 2026.